Objective: The aim of the study was to validate self-reported colorectal cancer (CRC) screening using the National Cancer Institute Colorectal Cancer Screening questionnaire.

Materials and Methods: 890 patients, ages 50 to 75 years, from the Minneapolis Veterans Affairs (VA) Medical Center were surveyed by mail. Phone administration was attempted with mail nonresponders. VA and non-VA records were combined for the reference standard. Sensitivity, specificity, concordance, and report-to-records ratio (R2R) were estimated for overall and test-specific CRC adherence among respondents providing complete medical records. Secondary analyses examined variation in estimates by patient characteristics, treatment of missing and uncertain responses, and whether a strict or liberal time interval was used for assessing concordance.

Results: Complete medical records were available for 345 of the 686 survey responders. For overall adherence, sensitivity was 0.98, specificity was 0.59, concordance was 0.88, and R2R was 1.14. Sensitivity was 0.82 for fecal occult blood test (FOBT), 0.75 for sigmoidoscopy, 0.97 for colonoscopy, and 0.63 for double-contrast barium enema (DCBE). Specificity was 0.89 for FOBT, 0.76 for sigmoidoscopy, 0.72 for colonoscopy, and 0.85 for DCBE. Concordance was >0.80 for all tests other than sigmoidoscopy (0.76). R2R was 1.31 for FOBT, 1.33 for sigmoidoscopy, 1.42 for colonoscopy, and 6.13 for DCBE. The R2R was lower for a combined sigmoidoscopy and colonoscopy measure. Overreporting was more pronounced for older, less-educated individuals with no family history of CRC. Sensitivity and R2R improved using a liberal interval and treating uncertain responses as nonadherent (versus missing), but differences were not statistically significant.

Conclusions: Self-reported CRC screening validity is generally acceptable and robust across definitional decisions, but varies by screening test and patient characteristics. (Cancer Epidemiol Biomarkers Prev 2008;17(4):768–76)

Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer death among both men and women in the United States (1). Various CRC prevention and early detection methods have been shown to substantially reduce CRC mortality (2-4). Current screening guidelines recommend that men and women, ages 50 years and older, have either a fecal occult blood test (FOBT) annually, sigmoidoscopy or double contrast barium enema (DCBE) every 5 years, colonoscopy every 10 years, or a combination of annual FOBT and sigmoidoscopy every 5 years (5, 6). Accurately assessing adherence to these guidelines is important for clinical decision making, quality assurance, and research.

Self-report is a critical source of information on CRC screening adherence for a variety of reasons. Perhaps the most obvious reason is that self-report is often the only available source of this information, particularly at the population level. Additionally, however, self-report may be the most efficient means for collecting this information in some circumstances, given that (a) the various CRC screening procedures endorsed are not all conducted in the same clinical settings and therefore may not be documented in a single location and (b) the data privacy restrictions imposed by the Health Insurance Portability and Accountability Act markedly complicate gathering medical data from multiple sources. Despite these advantages, self-reported data on screening behavior can be misleading if it is systematically biased. Furthermore, the substantial variation, across prior studies and surveillance efforts, in how self-reported CRC screening behavior is collected and reported makes it difficult to draw conclusions about current adherence levels, trends, determinants, and how to modify them (7).

In recognition of the value of self-reported CRC screening data and the importance of standardized measures for facilitating efforts to improve CRC screening rates, the National Cancer Institute (NCI) developed a core set of questions for measuring self-reported CRC screening behavior (7) that reflect the CRC screening guidelines published by the American Cancer Society and the U.S. Preventive Services Task Force between 2001 and 2002 (6, 8). This questionnaire is called the NCI Colorectal Cancer Screening questionnaire (or NCI CRCS questionnaire). Although previous studies have examined the validity and reliability of self-reported CRC screening measures (9-19), none included DCBE, most did not include colonoscopy, and most were conducted on highly educated, racially homogenous samples in health maintenance organizations and are not readily generalizable to disadvantaged populations.

This study validated the NCI CRCS questionnaire measures in a population of low-income veterans using a mailed survey with phone follow-up. Common measures of validity (sensitivity, specificity, concordance, and report-to-records ratio) were estimated for overall adherence (by any test) and test-specific adherence (FOBT, sigmoidoscopy, colonoscopy, either sigmoidoscopy or colonoscopy, and DCBE separately). Secondary analyses examined variation in validity estimates by patient demographic and health characteristics, treatment of missing and uncertain responses, and whether a strict or liberal time interval was used for assessing concordance.

Population and Setting

The study sample was drawn from the population of male and female patients receiving care from the Minneapolis Veterans Affairs (VA) Medical Center. This medical center is a large, multispecialty teaching hospital that, in 2005, had over 200 practicing physicians and nearly 75,000 enrolled patients. The patient population cared for at this medical center is primarily low-income veterans (due to health services eligibility criteria), elderly (50%, ≥65 y), male (93%), and Caucasian (>85%). In 2006, ∼75% of the population were adherent to CRC screening guidelines, and FOBT was the primary screening modality used.

Eligibility Criteria

Study participants included male and female veterans age 50 to 75 y who had one or more primary care visits to Minneapolis VA Medical Center between October 2003 and September 2005. Individuals with CRC diagnoses, individuals enrolled in VA adult day care and nursing home facilities, and individuals with dementia or Alzheimer's disease documented in VA medical records were excluded. Females and African Americans were oversampled to facilitate sex and race comparisons.

Sampling

Figure 1 illustrates the sample selection details. A total of 29,882 subjects were identified as eligible for the sample (715 females, 490 African American males, and 28,677 non–African American males). A random sample of 900 eligible patients, stratified by sex and race, was drawn from the pool of eligible patients to produce a survey recruitment sample containing 300 females, 300 African American males, and 300 non–African American males. Ten patients were withdrawn from this sample before survey recruitment, either because they were deceased (n = 6) or nonveterans/patients not enrolled at the Minneapolis VA Medical Center (n = 4). A total of 686 (77%) of the remaining 890 participants completed the survey, 627 (70%) by mail and 59 (7%) by phone. Survey nonrespondents were more likely than respondents to be of ages 50 to 64 y (81% versus 67%, P = 0.0002), African American (52% versus 29%, P < 0.0.0001), male (73% versus 65%, P = 0.04), and have a mental health diagnosis (78 versus 63%, P < 0.0001) but did not differ statistically significantly from respondents on the Charlson Comorbidity Index.

Figure 1.

Subject flow diagram.

Figure 1.

Subject flow diagram.

Close modal

We obtained a waiver of informed consent to access VA medical records which allowed us to access any VA medical records data on CRC screening procedures received by study participants in the last 10 y. However, as it is possible that some veterans may have received screening procedures from non-VA facilities, all veterans surveyed were asked to provide clinical information and written authorization to access any non-VA medical records. We did not explicitly ask veterans if they received all of their care from the VA, but some veterans offered this unsolicited information. Patients were included in our final validation analyses if (a) we obtained complete non-VA medical records for them or (b) they indicated that they received all of their care through the VA. We obtained complete non-VA medical records for 163 veterans, and 182 veterans indicated that they received all of their care through the VA, leaving 345 participants (50% of the total sample of 686 survey respondents) available for the validation analysis. A total of 336 participants (97%) included in the analysis completed the survey by mail, and nine (3%) completed the survey by phone.

Data Collection

Self-Reported Survey Data. Self-reported CRC screening behaviors were collected from a mixed-mode survey, in which a mailed questionnaire was the primary mode and phone was the secondary mode. The survey was conducted between March and June 2006. The initial survey mailing included a cover letter, the questionnaire, and a $2 bill cash incentive. A reminder postcard was mailed ∼1 wk after the first survey mailing. A second survey mailing (with no incentive) was mailed to those who did not return a questionnaire within 3 to 4 wk of the first mailing. Phone administration of the survey was attempted with all participants who did not return a questionnaire within 3 wk of the second survey mailing. The 14-page questionnaire included the NCI CRCS measures (7), as well as measures of CRC screening knowledge and attitudes and patient demographic and health characteristics. The self-reported CRC screening behavior section followed the NCI CRCS question wording and order with two exceptions: (a) we asked only for the timing and date of the most recent test received and (b) we added the following question directly after the “ever heard of” question regarding physician recommendation: “In the past 12 months, did a doctor, nurse, or other health professional advise you to have a [screening test type]?”

Medical Records Data. To obtain a complete history of testing behavior, medical record information was compiled from both VA medical records and non-VA medical records. VA medical records were available for all subjects in the study sample. However, we needed to request a release of information form for any non-VA medical records. For participants who completed and signed a non-VA medical records release form, medical records for FOBTs, sigmoidoscopies, colonoscopies, and DCBEs were requested from all sources of health care services identified by the respondent as received outside the VA. We requested records for subjects who reported being screened, as well as those who reported not being screened. We received medical records from all hospitals and clinics where we requested them. Including these non-VA medical records added 4 FOBTs, 2 sigmoidoscopies, 58 colonoscopies, and 2 DCBEs to our counts of the number adherent with test-specific guidelines for each of these procedures.

All VA and non-VA records were reviewed to determine the types of tests (FOBT, sigmoidoscopies, colonoscopies, and DCBEs), dates of tests, and if possible, indications for the tests. For the VA medical records, this information was abstracted electronically. For non-VA medical records received from clinics and hospitals, all relevant outpatient notes and laboratory reports in the specified time period were reviewed by a trained member of the study team using a standardized medical record abstraction form. To ensure quality control, ∼10% of these records were independently reviewed by a second trained team member, with 97% agreement across all category assignments. When necessary, an expert physician was consulted to resolve disagreements.

Measures

We examined sensitivity, specificity, concordance, and report-to-records ratio (defined below) for both overall and test-specific adherence measures. Because we were concerned about possible confusion between sigmoidoscopy and colonoscopy among respondents, we calculated validity estimates for sigmoidoscopy and colonoscopy separately, as well as for a combined endoscopy measure (adherent with either sigmoidoscopy or colonoscopy). Below, we describe how adherence status was assessed from self-reported and medical records data sources.

Assessing Self-Reported Adherence Status. Three items from the NCI CRCS questionnaire (7) were used to assess self-reported CRC screening adherence status: (a) a dichotomous question regarding whether they ever had the CRC test in question, (b) a categorical interval question asking when they had their most recent (CRC test type), and (c) an exact-date question asking for the specific month and year of the most recent test. Coding of adherence status using these three questions is described in detail below.

Our decisions about which question to prioritize in our coding procedures was informed by the relative distribution of missing responses across the categorical and exact-date questions. Among respondents that said they had ever been screened, participants were more likely to respond to the interval question (which appeared first in the questionnaire order) than the exact-date question. Indeed, although consistently >97% provided a response to the interval question (regardless of test type), only 47% answered the exact-date question for FOBT and colonoscopy, only 37% for sigmoidoscopy, and only 19% for DCBE. Because it had fewer missing responses than the exact-date question, we first examined responses to the categorical question “when did you have your most recent [screening test type].” If the response to this question reflected adherence with the recommended time interval for that procedure (i.e., “a year ago or less” for FOBT; either “a year ago or less” or “less than 1 but not more than 5 years ago” for sigmoidoscopy and DCBE; and either “a year ago or less,” “more than 1 but not more than 5 years ago,” or “more than 5 but not more than 10 years ago” for colonoscopy), the respondent was coded as adherent with screening guidelines based on self-report. For the combined sigmoidoscopy and colonoscopy estimates, we coded, as adherent, any respondent who reported receiving either a sigmoidoscopy in the past 5 y or a colonoscopy in the past 10 y. If a respondent did not answer the above timing question or indicated they were not sure but they provided a specific month and year for their most recent procedure in the follow-up date question, adherence was determined based on the comparison between the survey completion date and the procedure date provided. If adherence status was still not clear (i.e., no month and year were provided), we then checked the participant's response to the question regarding whether the procedure was ever done. If the answer to this question was “no,” then nonadherence status was assigned. We compared estimates that treated the remaining cases as “missing” to estimates that assigned these cases a status of “nonadherent”.

Assessing Medical Records Adherence Status. If a participant had documentation in either their VA or non-VA medical records (if applicable) of having received a test within the recommended timeframe (i.e., 12 mo before the survey completion date for FOBT, 5 y before the survey completion date for sigmoidoscopy and DCBE, and 10 y before the survey completion date for colonoscopy), they were coded as adherent with screening guidelines based on medical records (strict interval definition). For the combined sigmoidoscopy and colonoscopy measures, individuals were coded as adherent if their medical records documented receipt of either a sigmoidoscopy in the past 5 y or a colonoscopy in the past 10 y.

Secondary analyses recalculated the validity estimates defined below using a more liberal agreement window (FOBT within 15 mo of the survey completion date, sigmoidoscopy or DCBE within 5.5 y of the survey completion date, or colonoscopy within 11 y of the survey completion date). Because we classified self-reported screening status first using the categorical response question and used responses regarding the exact month and year only when the categorical response was missing or “don't know” (which occurred in <12% of cases across all test types), this definition change was more likely to affect adherence status based on medical records data than adherence status based on self-reported data. Overall CRC screening adherence for both self-report and medical records was defined as adherence with any one of the test-specific adherence measures.

Validity Measures.Table 1 provides the raw data from which all validity measures were derived. Sensitivity is the proportion of participants that reported having the test among those who had documentation of having a test in the medical record. Specificity is the proportion of participants that reported not having a test among those who had no documentation of having the test in the medical record. Concordance is the proportion of participants whose self-reported and medical records adherence status agrees. The report-to-records ratio (R2R) is the number of participants reporting a test divided by the number of tests in the record. A report-to-records ratio of >1 indicates overreporting, and a ratio of <1 indicates underreporting. There are no established standards for acceptable ranges on the above measures. However, based on the approach used in one recent validation study (20), we considered estimates of ≥0.9 to indicate excellent agreement for sensitivity, specificity, and concordance; estimates of ≥0.8 to indicate good agreement; estimates ≥0.7 to indicate fair agreement; and estimates <0.7 to indicate poor agreement.

Table 1.

Cross-classification of self-report and medical records–based adherence for Minneapolis VA Medical Center patients, 2006

Medical records
Strict*
Liberal
AdherentNonadherentAdherentNonadherent
Overall      
Self-report Adherent 229 36 234 31 
 Nonadherent 51 50 
 In determinant 10 15 10 15 
FOBT      
Self-report Adherent 51 30 56 25 
 Nonadherent 11 233 14 230 
 In determinant 20 19 
Sigmoidoscopy      
Self-report Adherent 69 54 72 51 
 Nonadherent 23 168 24 167 
 In determinant 13 18 14 17 
Colonoscopy      
Self-report Adherent 120 56 120 56 
 Nonadherent 143 143 
 In determinant 16 16 
Sigmoidoscopy + colonoscopy      
Self-report Adherent 200 38 201 37 
 Nonadherent 82 81 
 In determinant 
Double contrast barium enema      
Self-report Adherent 43 41 
 Nonadherent 253 253 
 In determinant 39 39 
Medical records
Strict*
Liberal
AdherentNonadherentAdherentNonadherent
Overall      
Self-report Adherent 229 36 234 31 
 Nonadherent 51 50 
 In determinant 10 15 10 15 
FOBT      
Self-report Adherent 51 30 56 25 
 Nonadherent 11 233 14 230 
 In determinant 20 19 
Sigmoidoscopy      
Self-report Adherent 69 54 72 51 
 Nonadherent 23 168 24 167 
 In determinant 13 18 14 17 
Colonoscopy      
Self-report Adherent 120 56 120 56 
 Nonadherent 143 143 
 In determinant 16 16 
Sigmoidoscopy + colonoscopy      
Self-report Adherent 200 38 201 37 
 Nonadherent 82 81 
 In determinant 
Double contrast barium enema      
Self-report Adherent 43 41 
 Nonadherent 253 253 
 In determinant 39 39 
*

Patient classified as adherent if they reported receiving either an FOBT within 12 mo before the survey completion date, a sigmoidoscopy or DCBE within 5 y before the survey completion date, or a colonoscopy within 10 y before the survey completion date.

Patient classified as adherent if they reported receiving either an FOBT within 15 mo before the survey completion date, a sigmoidoscopy or DCBE within 5.5 y before the survey completion date, or a colonoscopy within 11 y before the survey completion date.

Independent measures used to examine variation in validity measures were obtained either from VA medical records or from the questionnaire. Age (50-64 y versus 65-75 y), sex, and comorbidities were abstracted from VA medical records, and race (African American versus non–African American), education (≤high school, some college, ≥college graduate), income (≥$20,000, $20-40,000, >$40,000), marital status (married versus unmarried), and family history (yes versus no) were obtained from the questionnaire. Comorbidities were summarized using the Charlson Comorbidity Index score (21, 22) and a measure of mental health diagnoses, which categorized individuals into three groups: (a) no mental health diagnoses, (b) single psychiatric (ICD-9 codes 290-302 and 306-311) or substance abuse–related (ICD-9 codes 303-305) diagnosis, or (c) dual diagnosis (psychiatric and substance abuse). We included measures of mental health diagnoses because they could conceivably affect the accuracy of recall and are not captured in the Charlson Comorbidity Index.

Analysis and Sample Size Determination

The sample size for this study was selected to maximize power for comparing validity estimates by sex and race. Power calculations were based on the assumption that both of the two subgroups would have a minimum estimate of 70% for sensitivity, specificity, or concordance and that, in each subgroup, at least 50% of the participants had complete medical records available. We had at least 81% power to detect a 15-percentage-point-or-greater difference in sensitivity, specificity, and concordance across sex and race subgroups.

Confidence intervals for the validity measures were calculated using bootstrapping methods due to nonnormal sampling distributions. This involved randomly drawing 10,000 samples, with replacement, from the original sample (n = 345), ordering the point estimates computed from each of these bootstrap samples from low to high, and selecting the point estimates corresponding to the 2.5th and 97.5th percentiles as the limits defining the 95% confidence interval.

Human Subjects

The Minneapolis VA Medical Center Subcommittee for Human Studies approved the study protocol.

Sample Characteristics

Table 2 presents the characteristics of the 345 patients included in the validation analyses (i.e., those for whom we could confirm we had complete medical records), as well as the 341 patients who were not included in the analysis because we could not confirm that we had complete medical records data for them. The validation sample had a statistically significantly higher proportion of Whites and of married persons compared with those not included. Otherwise, the excluded patients did not differ from those included in our validation analyses. In both samples, the majority were 50 to 64 years of age, Caucasian, male, married, had greater than a high school education, had a household income of <$40,000/y, had no family history of CRC, had a Charlson comorbidity score of <1, and had either a psychiatric, substance abuse, or dual (i.e., psychiatric and substance abuse) mental health diagnosis.

Table 2.

Sample characteristics for Minneapolis VA Medical Center patients, 2006

Demographic and clinical characteristicsResponding participants
P for the observed difference
Validation sample (n = 345), n (%)Excluded from validation sample (n = 341), n (%)
Age    
    50-64 y 225 (65%) 238 (70%) 0.20 
    65 y and older 120 (35%) 103 (30%)  
Race    
    American Indian/Alaskan native 10 (3%) 11 (3%) 0.01 
    Asian 0 (0%) 0 (0%)  
    African American 85 (25%) 110 (32%)  
    Native Hawaiian/Pacific Islander 0 (0%) 3 (1%)  
    White 241 (70%) 205 (60%)  
    Hispanic 3 (1%) 0 (0%)  
    Other 5 (1%) 11 (3%)  
    Unknown 1 (-) 1 (-)  
Gender    
    Female 128 (37%) 113 (33%) 0.28 
    Male 217 (63%) 228 (67%)  
Education    
    ≤High school 104 (32%) 122 (37%) 0.55 
    Some college 137 (41%) 130 (39%)  
    ≥College graduate 92 (28%) 83 (25%)  
    Unknown 12 (-) 6 (-)  
Marital status    
    Married/living with someone 206 (61%) 170 (51%) 0.01 
    Not married 132 (39%) 164 (50%)  
    Unknown 7 (-) 7 (-)  
Annual household income    
    <$20,000 122 (38%) 199 (40%) 0.67 
    $20,000-40,000 103 (32%) 96 (32%)  
    ≥$40,000 98 (30%) 84 (28%)  
    Unknown 22 (-) 42 (-)  
Family history of CRC    
    Yes 69 (24%) 56 (20%) 0.33 
    No 220 (76%) 218 (80%)  
    Unknown 56 (-) 67 (-)  
Charlson comorbidity index    
    Mean 1.6 1.7 0.34 
    0 140 (41%) 137 (40%) 0.50 
    1 86 (25%) 71 (21%)  
    2 43 (13%) 45 (13%)  
    3 or more 76 (22%) 88 (26%)  
Mental health diagnosis status    
    No mental health diagnosis 122 (35%) 130 (38%) 0.45 
    Psychological or substance abuse 128 (37%) 112 (33%) 0.24 
    Dual diagnosis 95 (28%) 99 (29%) 0.66 
Demographic and clinical characteristicsResponding participants
P for the observed difference
Validation sample (n = 345), n (%)Excluded from validation sample (n = 341), n (%)
Age    
    50-64 y 225 (65%) 238 (70%) 0.20 
    65 y and older 120 (35%) 103 (30%)  
Race    
    American Indian/Alaskan native 10 (3%) 11 (3%) 0.01 
    Asian 0 (0%) 0 (0%)  
    African American 85 (25%) 110 (32%)  
    Native Hawaiian/Pacific Islander 0 (0%) 3 (1%)  
    White 241 (70%) 205 (60%)  
    Hispanic 3 (1%) 0 (0%)  
    Other 5 (1%) 11 (3%)  
    Unknown 1 (-) 1 (-)  
Gender    
    Female 128 (37%) 113 (33%) 0.28 
    Male 217 (63%) 228 (67%)  
Education    
    ≤High school 104 (32%) 122 (37%) 0.55 
    Some college 137 (41%) 130 (39%)  
    ≥College graduate 92 (28%) 83 (25%)  
    Unknown 12 (-) 6 (-)  
Marital status    
    Married/living with someone 206 (61%) 170 (51%) 0.01 
    Not married 132 (39%) 164 (50%)  
    Unknown 7 (-) 7 (-)  
Annual household income    
    <$20,000 122 (38%) 199 (40%) 0.67 
    $20,000-40,000 103 (32%) 96 (32%)  
    ≥$40,000 98 (30%) 84 (28%)  
    Unknown 22 (-) 42 (-)  
Family history of CRC    
    Yes 69 (24%) 56 (20%) 0.33 
    No 220 (76%) 218 (80%)  
    Unknown 56 (-) 67 (-)  
Charlson comorbidity index    
    Mean 1.6 1.7 0.34 
    0 140 (41%) 137 (40%) 0.50 
    1 86 (25%) 71 (21%)  
    2 43 (13%) 45 (13%)  
    3 or more 76 (22%) 88 (26%)  
Mental health diagnosis status    
    No mental health diagnosis 122 (35%) 130 (38%) 0.45 
    Psychological or substance abuse 128 (37%) 112 (33%) 0.24 
    Dual diagnosis 95 (28%) 99 (29%) 0.66 

Validity of Self-Reported Screening Measures

Table 3 presents overall and test-specific validity estimates and corresponding 95% confidence intervals for sensitivity, specificity, R2R, and concordance. The first panel of this table presents estimates derived from our primary analyses, which used a strict interval definition and treated missing and uncertain responses as missing. For overall adherence, using this definition, sensitivity was excellent (0.98) and concordance was good (0.88). Specificity, however, was poor (0.59), and R2R was 1.14. Test-specific validity estimates varied considerably. Sensitivity was excellent for colonoscopy (0.97) and good for FOBT (0.82), but fair for sigmoidoscopy (0.75) and poor for DCBE (0.63). Specificity was good for FOBT (0.89) and DCBE (0.85), but fair for sigmoidoscopy (0.76) and colonoscopy (0.72). Concordance was good for all tests other than sigmoidoscopy (0.73). Adherence was overreported for all tests (as indicated by R2Rs of >1 in all cases), but overreporting was greatest for DCBE (R2R of 6.13). Overreporting was lowest for FOBT (R2R of 1.31), followed by sigmoidoscopy (1.33) and colonoscopy (1.42). The combined sigmoidoscopy and colonoscopy estimates did similar to or better than the separate sigmoidoscopy and colonoscopy estimates on all measures, except specificity (which was consistently fair for the separate estimates, but fair-to-poor for the combined estimate). The R2R for the combined sigmoidoscopy and colonoscopy measure treating uncertain responses as missing, at 1.14, was markedly lower than the R2Rs for the separate sigmoidoscopy and colonoscopy measures.

Table 3.

Overall and mode-specific validity estimates and 95% confidence intervals for Minneapolis VA Medical Center patients, 2006

CRC screening modeMeasures of accuracy of self-reported CRC screening compliance
Sensitivity*SpecificityReport-to-records ratioConcordance§
Strict, don't know as missing     
    Any mode 0.98 (0.96-1.00) 0.59 (0.49-0.68) 1.14 (1.08-1.20) 0.88 (0.84-0.91) 
    FOBT 0.82 (0.72-0.91) 0.89 (0.85-0.92) 1.31 (1.11-1.57) 0.87 (0.84-0.91) 
    Sigmoidoscopy 0.75 (0.66-0.84) 0.76 (0.70-0.82) 1.33 (1.13-1.55) 0.76 (0.71-0.81) 
    Colonoscopy 0.97 (0.93-1.00) 0.72 (0.66-0.78) 1.42 (1.27-1.58) 0.81 (0.77-0.86) 
    Sigmoidoscopy + colonoscopy 0.96 (0.93-0.99) 0.68 (0.60-0.76) 1.14 (1.08,0.22) 0.86 (0.82-0.90) 
    DCBE 0.63 (0.33-1.00) 0.85 (0.81-0.89) 6.13 (3.38-12.00) 0.85 (0.80-0.89) 
Liberal, don't know as missing     
    Any mode 0.98 (0.96-1.00) 0.62 (0.50-0.72) 1.11 (1.06-1.16) 0.89 (0.85-0.92) 
    FOBT 0.80 (0.70-0.89) 0.90 (0.86-0.93) 1.16 (0.99-1.35) 0.88 (0.85-0.91) 
    Sigmoidoscopy 0.75 (0.66-0.83) 0.77 (0.71-0.82) 1.28 (1.11-1.49) 0.76 (0.72-0.81) 
    Colonoscopy 0.97 (0.93-0.99) 0.72 (0.65-0.78) 1.42 (1.28-1.58) 0.81 (0.77-0.86) 
    Sigmoidoscopy + colonoscopy 0.96 (0.93-0.98) 0.69 (0.59-0.77) 1.13 (1.07-0.12) 0.86 (0.82-0.90) 
    DCBE 0.70 (0.45-1.00) 0.86 (0.82-0.90) 4.90 (2.80-8.43) 0.85 (0.82-0.90) 
Strict, don't know as noncompliant     
    Any mode 0.95 (0.92-0.97) 0.65 (0.55-0.74) 1.09 (1.04-1.15) 0.86 (0.82-0.90) 
    FOBT 0.82 (0.73-0.91) 0.89 (0.86-0.93) 1.31 (1.10-1.56) 0.88 (0.85-0.92) 
    Sigmoidoscopy 0.67 (0.58-0.75) 0.78 (0.72-0.83) 1.18 (1.01-1.39) 0.74 (0.70-0.79) 
    Colonoscopy 0.93 (0.89-0.97) 0.74 (0.68-0.80) 1.36 (1.22-1.52) 0.81 (0.77-0.86) 
    Sigmoidoscopy + colonoscopy 0.93 (0.89-0.96) 0.71 (0.63-0.78) 1.10 (1.03-1.18) 0.84 (0.80-0.88) 
    DCBE 0.50 (0.25-0.88) 0.87 (0.83-0.90) 4.90 (2.86-9.20) 0.86 (0.83-0.90) 
Liberal, don't know noncompliant     
    Any mode 0.94 (0.92-0.97) 0.68 (0.58-0.76) 1.07 (1.01-1.12) 0.87 (0.83-0.91) 
    FOBT 0.79 (0.69-0.88) 0.91 (0.87-0.94) 1.14 (0.96-1.36) 0.88 (0.85-0.92) 
    Sigmoidoscopy 0.66 (0.58-0.76) 0.78 (0.73-0.84) 1.13 (0.96-1.31) 0.74 (0.70-0.79) 
    Colonoscopy 0.93 (0.89-0.97) 0.74 (0.68-0.80) 1.36 (1.23-1.51) 0.81 (0.78-0.86) 
    Sigmoidoscopy + colonoscopy 0.92 (0.89-0.96) 0.71 (0.62-0.78) 1.09 (1.03-1.17) 0.84 (0.81-0.88) 
    DCBE 0.58 (0.33-0.89) 0.87 (0.84-0.91) 4.08 (2.46-7.00) 0.86 (0.83-0.90) 
CRC screening modeMeasures of accuracy of self-reported CRC screening compliance
Sensitivity*SpecificityReport-to-records ratioConcordance§
Strict, don't know as missing     
    Any mode 0.98 (0.96-1.00) 0.59 (0.49-0.68) 1.14 (1.08-1.20) 0.88 (0.84-0.91) 
    FOBT 0.82 (0.72-0.91) 0.89 (0.85-0.92) 1.31 (1.11-1.57) 0.87 (0.84-0.91) 
    Sigmoidoscopy 0.75 (0.66-0.84) 0.76 (0.70-0.82) 1.33 (1.13-1.55) 0.76 (0.71-0.81) 
    Colonoscopy 0.97 (0.93-1.00) 0.72 (0.66-0.78) 1.42 (1.27-1.58) 0.81 (0.77-0.86) 
    Sigmoidoscopy + colonoscopy 0.96 (0.93-0.99) 0.68 (0.60-0.76) 1.14 (1.08,0.22) 0.86 (0.82-0.90) 
    DCBE 0.63 (0.33-1.00) 0.85 (0.81-0.89) 6.13 (3.38-12.00) 0.85 (0.80-0.89) 
Liberal, don't know as missing     
    Any mode 0.98 (0.96-1.00) 0.62 (0.50-0.72) 1.11 (1.06-1.16) 0.89 (0.85-0.92) 
    FOBT 0.80 (0.70-0.89) 0.90 (0.86-0.93) 1.16 (0.99-1.35) 0.88 (0.85-0.91) 
    Sigmoidoscopy 0.75 (0.66-0.83) 0.77 (0.71-0.82) 1.28 (1.11-1.49) 0.76 (0.72-0.81) 
    Colonoscopy 0.97 (0.93-0.99) 0.72 (0.65-0.78) 1.42 (1.28-1.58) 0.81 (0.77-0.86) 
    Sigmoidoscopy + colonoscopy 0.96 (0.93-0.98) 0.69 (0.59-0.77) 1.13 (1.07-0.12) 0.86 (0.82-0.90) 
    DCBE 0.70 (0.45-1.00) 0.86 (0.82-0.90) 4.90 (2.80-8.43) 0.85 (0.82-0.90) 
Strict, don't know as noncompliant     
    Any mode 0.95 (0.92-0.97) 0.65 (0.55-0.74) 1.09 (1.04-1.15) 0.86 (0.82-0.90) 
    FOBT 0.82 (0.73-0.91) 0.89 (0.86-0.93) 1.31 (1.10-1.56) 0.88 (0.85-0.92) 
    Sigmoidoscopy 0.67 (0.58-0.75) 0.78 (0.72-0.83) 1.18 (1.01-1.39) 0.74 (0.70-0.79) 
    Colonoscopy 0.93 (0.89-0.97) 0.74 (0.68-0.80) 1.36 (1.22-1.52) 0.81 (0.77-0.86) 
    Sigmoidoscopy + colonoscopy 0.93 (0.89-0.96) 0.71 (0.63-0.78) 1.10 (1.03-1.18) 0.84 (0.80-0.88) 
    DCBE 0.50 (0.25-0.88) 0.87 (0.83-0.90) 4.90 (2.86-9.20) 0.86 (0.83-0.90) 
Liberal, don't know noncompliant     
    Any mode 0.94 (0.92-0.97) 0.68 (0.58-0.76) 1.07 (1.01-1.12) 0.87 (0.83-0.91) 
    FOBT 0.79 (0.69-0.88) 0.91 (0.87-0.94) 1.14 (0.96-1.36) 0.88 (0.85-0.92) 
    Sigmoidoscopy 0.66 (0.58-0.76) 0.78 (0.73-0.84) 1.13 (0.96-1.31) 0.74 (0.70-0.79) 
    Colonoscopy 0.93 (0.89-0.97) 0.74 (0.68-0.80) 1.36 (1.23-1.51) 0.81 (0.78-0.86) 
    Sigmoidoscopy + colonoscopy 0.92 (0.89-0.96) 0.71 (0.62-0.78) 1.09 (1.03-1.17) 0.84 (0.81-0.88) 
    DCBE 0.58 (0.33-0.89) 0.87 (0.84-0.91) 4.08 (2.46-7.00) 0.86 (0.83-0.90) 
*

Defined as the proportion of participants that reported having the test among those who had documentation of having a test in the medical record.

Defined as the proportion of participants that reported not having a test among those who had no documentation of having the test in the medical record.

Defined as the number of participants reporting a test divided by the number of tests in the record. A report-to-records ratio of >1 indicates overreporting, and a ratio of <1 indicates under reporting.

§

Defined as the proportion of participants whose self-reported and medical records adherence status agrees.

Patient classified as adherent if they reported receiving either an FOBT within 12 mo before the survey completion date, a sigmoidoscopy or DCBE within 5 y before the survey completion date, or a colonoscopy within 10 y before the survey completion date.

Patient classified as adherent if they reported receiving either an FOBT within 15 mo before the survey completion date, a sigmoidoscopy or DCBE within 5.5 y before the survey completion date, or a colonoscopy within 11 y before the survey completion date.

Variation in Validity Estimates Across Definitional Decisions

As shown in Table 3, using a liberal, rather than a strict, interval for assessing medical records adherence generally resulted in comparable or more favorable validity estimates, but none of the differences between strict and liberal validity estimates were statistically significant. Treating missing and uncertain self-report responses as nonadherent (rather than missing) generally resulted in less favorable sensitivity estimates and more favorable estimates of specificity, concordance, and R2R. As with the differences in interval definitions, however, none of the differences in estimates due to treatment of uncertain and missing responses were statistically significant.

Variation in Validity Estimates Across Population Subgroups

Subgroup estimates for overall adherence, shown in Table 4, were calculated using a strict interval for assessing adherence in the medical record and treating missing and uncertain self-report responses as missing (rather than nonadherent). Although sensitivity and concordance were consistently good-to-excellent across all subgroups and specificity was consistently fair-to-poor across all subgroups, the extent of overreporting (as assessed by the R2R) was statistically significantly more pronounced for older individuals, those with less than a high-school education, and those without a family history of CRC.

Table 4.

Validity estimates and 95% confidence intervals for overall compliance, by patient characteristics for Minneapolis VA Medical Center patients, 2006

Patient characteristicsMeasures of accuracy of self-reported overall CRC screening compliance
SensitivitySpecificityReport-to-records ratioConcordance
Age     
    50-64 y 0.97 (0.95-0.99)* 0.67 (0.54-0.79)* 1.09 (1.03-1.16)* 0.89 (0.85-0.94) 
    65-75 y 1.00 (1.00-1.00)* 0.45 (0.29-0.63)* 1.22 (1.12-1.35)* 0.84 (0.78-0.91) 
Race     
    African American 0.98 (0.93-1.00) 0.61 (0.40-0.81) 1.15 (1.04-1.29) 0.87 (0.80-0.95) 
    Non–African American 0.98 (0.96-1.00) 0.58 (0.45-0.69) 1.13 (1.07-1.21) 0.88 (0.84-0.92) 
Gender     
    Male 0.99 (0.97-1.00) 0.52 (0.38-0.65) 1.17 (1.09-1.25) 0.86 (0.81-0.91) 
    Female 0.98 (0.94-1.00) 0.71 (0.55-0.86) 1.08 (1.01-1.17) 0.91 (0.86-0.97) 
Education     
    ≤High school 1.00 (1.00-1.00) 0.46 (0.27-0.66)* 1.21 (1.11-1.35)* 0.85 (0.78-0.92)* 
    Some college 0.97 (0.92-1.00) 0.59 (0.44-0.73) 1.16 (1.06-1.27) 0.85 (0.79-0.91) 
    College graduate 1.00 (1.00-1.00) 0.79 (0.60-0.95)* 1.06 (1.01-1.12)* 0.95 (0.92-1.00)* 
Marital status     
    Married 0.97 (0.94-0.99) 0.58 (0.45-0.71) 1.13 (1.06-1.22) 0.86 (0.82-0.91) 
    Not married 1.00 (1.00-1.00) 0.61 (0.45-0.76) 1.14 (1.06-1.23) 0.90 (0.85-0.96) 
Family history     
    Yes 0.98 (0.95-1.00) 0.43 (0.00-0.86) 1.05 (0.98-1.12)* 0.93 (0.88-0.99) 
    No 0.99 (0.97-1.00) 0.58 (0.43-0.69) 1.19 (1.11-1.29)* 0.86 (0.80-0.91) 
Annual household income     
    ≤$20,000 0.99 (0.96-1.00) 0.58 (0.40-0.75) 1.15 (1.06-1.25) 0.88 (0.82-0.94) 
    $20,001-40,000 1.00 (1.00-1.00) 0.62 (0.44-0.80) 1.14 (1.06-1.25) 0.90 (0.85-0.96) 
    >$40,000 0.97 (0.92-1.00) 0.59 (0.35-0.79) 1.10 (1.00-1.21) 0.88 (0.81-0.96) 
Comorbidity index     
    0 0.99 (0.96-1.00) 0.53 (0.35-0.68) 1.20 (1.10-1.32) 0.85 (0.78-0.92) 
    1 0.98 (0.95-1.00) 0.58 (0.33-0.81) 1.11 (1.01-1.22) 0.89 (0.83-0.96) 
    2+ 0.98 (0.94-1.00) 0.68 (0.50-0.84) 1.09 (1.01-1.18) 0.90 (0.84-0.95) 
Mental health     
    No mental health diagnosis 0.97 (0.94-1.00) 0.51 (0.35-0.66) 1.22 (1.10-1.36) 0.82 (0.76-0.90) 
    Psychological or substance abuse 0.99 (0.97-1.00) 0.62 (0.42-0.80) 1.09 (1.03-1.18) 0.91 (0.86-0.96) 
    Dual diagnosis 0.98 (0.94-1.00) 0.68 (0.46-0.88) 1.10 (1.00-1.21) 0.90 (0.84-0.98) 
Patient characteristicsMeasures of accuracy of self-reported overall CRC screening compliance
SensitivitySpecificityReport-to-records ratioConcordance
Age     
    50-64 y 0.97 (0.95-0.99)* 0.67 (0.54-0.79)* 1.09 (1.03-1.16)* 0.89 (0.85-0.94) 
    65-75 y 1.00 (1.00-1.00)* 0.45 (0.29-0.63)* 1.22 (1.12-1.35)* 0.84 (0.78-0.91) 
Race     
    African American 0.98 (0.93-1.00) 0.61 (0.40-0.81) 1.15 (1.04-1.29) 0.87 (0.80-0.95) 
    Non–African American 0.98 (0.96-1.00) 0.58 (0.45-0.69) 1.13 (1.07-1.21) 0.88 (0.84-0.92) 
Gender     
    Male 0.99 (0.97-1.00) 0.52 (0.38-0.65) 1.17 (1.09-1.25) 0.86 (0.81-0.91) 
    Female 0.98 (0.94-1.00) 0.71 (0.55-0.86) 1.08 (1.01-1.17) 0.91 (0.86-0.97) 
Education     
    ≤High school 1.00 (1.00-1.00) 0.46 (0.27-0.66)* 1.21 (1.11-1.35)* 0.85 (0.78-0.92)* 
    Some college 0.97 (0.92-1.00) 0.59 (0.44-0.73) 1.16 (1.06-1.27) 0.85 (0.79-0.91) 
    College graduate 1.00 (1.00-1.00) 0.79 (0.60-0.95)* 1.06 (1.01-1.12)* 0.95 (0.92-1.00)* 
Marital status     
    Married 0.97 (0.94-0.99) 0.58 (0.45-0.71) 1.13 (1.06-1.22) 0.86 (0.82-0.91) 
    Not married 1.00 (1.00-1.00) 0.61 (0.45-0.76) 1.14 (1.06-1.23) 0.90 (0.85-0.96) 
Family history     
    Yes 0.98 (0.95-1.00) 0.43 (0.00-0.86) 1.05 (0.98-1.12)* 0.93 (0.88-0.99) 
    No 0.99 (0.97-1.00) 0.58 (0.43-0.69) 1.19 (1.11-1.29)* 0.86 (0.80-0.91) 
Annual household income     
    ≤$20,000 0.99 (0.96-1.00) 0.58 (0.40-0.75) 1.15 (1.06-1.25) 0.88 (0.82-0.94) 
    $20,001-40,000 1.00 (1.00-1.00) 0.62 (0.44-0.80) 1.14 (1.06-1.25) 0.90 (0.85-0.96) 
    >$40,000 0.97 (0.92-1.00) 0.59 (0.35-0.79) 1.10 (1.00-1.21) 0.88 (0.81-0.96) 
Comorbidity index     
    0 0.99 (0.96-1.00) 0.53 (0.35-0.68) 1.20 (1.10-1.32) 0.85 (0.78-0.92) 
    1 0.98 (0.95-1.00) 0.58 (0.33-0.81) 1.11 (1.01-1.22) 0.89 (0.83-0.96) 
    2+ 0.98 (0.94-1.00) 0.68 (0.50-0.84) 1.09 (1.01-1.18) 0.90 (0.84-0.95) 
Mental health     
    No mental health diagnosis 0.97 (0.94-1.00) 0.51 (0.35-0.66) 1.22 (1.10-1.36) 0.82 (0.76-0.90) 
    Psychological or substance abuse 0.99 (0.97-1.00) 0.62 (0.42-0.80) 1.09 (1.03-1.18) 0.91 (0.86-0.96) 
    Dual diagnosis 0.98 (0.94-1.00) 0.68 (0.46-0.88) 1.10 (1.00-1.21) 0.90 (0.84-0.98) 
*

Significant subgroup differences (i.e., 95% confidence interval for the difference between subgroups did not include 0).

This study evaluated the validity of the NCI CRCS questionnaire and examined the validity of all four CRC screening tests recommended in the U.S. Preventive Services Task Force and American Cancer Society guidelines. The results suggest that the validity of self-reported CRC screening adherence data collected from a population of low-income veterans using the NCI CRCS questionnaire is generally good and robust across definitional decisions, but varies by screening test and patient characteristics.

Sensitivity, specificity, concordance, and R2R estimates for overall adherence and DCBE have not been reported in prior studies. However, the validity estimates for FOBT, sigmoidoscopy, and colonoscopy found in this study are comparable with those reported in prior studies. Our R2R estimates for FOBT (1.14-1.31) are higher than the estimates reported in the only prior study reporting R2R estimates (1.03; ref. 14), but our sensitivity and concordance estimates for FOBT (0.79-0.82 and 0.87-0.88, respectively) are in the upper end of the range of estimates reported in prior studies (0.55-0.96 and 0.72-0.94; refs. 9, 13-19), and our specificity estimates (0.89-0.91) are higher than those reported in prior studies (0.58-0.87; refs. 9, 13-19). R2Rs have not been reported for sigmoidoscopy in prior studies, but our sensitivity (0.66-0.75), specificity (0.76-0.78), and concordance (0.74-0.76) estimates for sigmoidoscopy are in the middle of the range of estimates for these measures reported in prior studies (0.33-1.00, 0.53-0.96, and 0.63-0.96, respectively; refs. 9, 13, 15, 18, 19). Finally, our estimates of sensitivity for colonoscopy (0.93-0.97) are in the upper range of sensitivity estimates reported in prior studies (0.56-0.95; refs. 13, 18, 19), but our specificity estimates (0.72-0.74) are lower than those reported in prior studies (0.87-0.97; refs. 13, 18, 19), and the one prior study reporting concordance for colonoscopy (13) found a higher rate of concordance (0.94) than we did (0.81).

Consistent with prior studies examining the validity of self-reported CRC screening, we found overreporting was a more prevalent source of error in self-reported CRC screening than underreporting (9, 13, 14, 16, 19). However, under certain definitional choices (liberal interval and uncertain and missing responses treated as nonadherent), the estimated extent of overreporting for overall adherence observed in our study was minimal (R2R, 1.07). The fact that overreporting was most pronounced for colonoscopy may reflect the fact that this is the newest screening procedure of the four CRC screening procedures and, hence, the one with which our population is the least familiar. The primary screening tests used in the population sampled for this study are FOBT and sigmoidoscopy. Colonoscopy is primarily used for diagnostic purposes in this VA setting. The low sensitivity estimates for sigmoidoscopy and higher overreporting of colonoscopy found in this study may, in part, reflect confusion between sigmoidoscopy and colonoscopy. Indeed, we chose to report estimates for a combined endoscopy measure because we found that 55% of patients with false positive reports for either one of these endoscopic procedures had documentation of receiving the other endoscopic procedure in their medical record. Although we found the R2R and specificity decreased with the combined definition, the one prior study reporting validity estimates for a combined endoscopy measure found that the combined estimates did not differ markedly from the separate estimates (19).

Our analyses of subgroup variation in validity estimates for overall adherence found statistically significant subgroup differences for age, education, and family history. This variation across subgroups could have important implications for the comparability across studies, as well as for inference about subgroup differences in screening behavior within studies. Several prior studies validating self-report CRC screening behavior examined subgroup differences in validity estimates (12, 14-19). However, the findings regarding subgroup differences are inconsistent across studies. This variation in subgroup differences in validity estimates across studies makes it difficult to draw conclusions about the comparability of reporting patterns across population subgroups and may, in part, reflect the substantial variation in what specific reported screening patterns were being validated in each study. Indeed, no two prior studies that investigated the validity of self-reported CRC screening behavior validated the same measure and no prior study validated CRC screening measures using a definition driven by evidence-based and current recommended screening guidelines, as we did. Future validation studies should focus on evaluating the validity of those screening measures most likely to be used in surveillance and clinical practice (i.e., measures, such as those examined in this study, which assess adherence to recommended CRC screening guidelines).

Additional sources of variation in the screening definitions validated in existing studies include the time interval used to assess concordance between self-report and medical records data (i.e., exact-date match versus some other more liberal criterion) and how missing and uncertain responses to survey questions are handled in the analysis. The findings from this study suggest that validity estimates were improved when using a more liberal time interval for assessing adherence between self-report and medical records and when cases with missing or uncertain responses are treated as nonadherent with CRC screening guidelines (rather than missing). However, improvements in these estimates were not statistically significant. The effect of how missing and uncertain responses are handled on validity estimates will be the most consequential for studies with a high proportion of missing and uncertain responses. Only three prior CRC screening studies specified how missing and uncertain responses were handled in the analysis (9, 10, 13), and none provided information on the proportion of responses that were missing or uncertain. To facilitate comparisons, future studies should provide information on the extent of missing and uncertain responses and how they were handled in the analysis. Because a more liberal screening interval definition has been recommended for studies examining determinants of screening behavior and evaluating interventions designed to enhance adherence with screening recommendations (23), the liberal estimates reported in this study may be more appropriate for most applications.

The findings from this study must be qualified by a number of limitations. Firstly, the results of this study may not generalize to other populations and settings because they are based on the population of low-income veterans receiving care from just one VA medical facility. Secondly, although we structured our choice of measures and analysis plan based on the assumption that the medical records data used as the reference standard were complete, it is possible that for some participants this information was not complete (i.e., participants may have forgotten to identify some of their non-VA health care service providers). Finally, our analyses excluded those patients for whom we could not confirm that we had complete medical records information and minorities and unmarried individuals were overrepresented among those excluded. However, the fact that neither of these characteristics were statistically significantly associated with overall adherence validity estimates suggests that the overrepresentation of these groups among those excluded is unlikely to have biased our estimates. Despite these limitations, as one of the first studies to document the sensitivity of validity estimates to key definitional choices, the findings from this study make an important contribution to the literature on CRC screening behavior.

Grant support: VA Health Services Research and Development grant IIR 04-042-2.

1
American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society; 2007.
2
Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence.
Gastroenterology
2003
;
124
:
544
–60.
3
Selby JV, Friedman GD, Quesenberry CP, Jr., Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer.
N Engl J Med
1992
;
326
:
653
–7.
4
Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality.
J Natl Cancer Inst
1992
;
84
:
1572
–5.
5
Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003.
CA Cancer J Clin
2003
;
53
:
27
–43.
6
U.S. Preventive Services Task Force. Colorectal Cancer Screening Guidelines. Agency for Healthcare Research and Quality, Rockville, Maryland. 2002.
7
Vernon SW, Meissner H, Klabunde C, et al. Measures for ascertaining use of colorectal cancer screening in behavioral, health services, and epidemiologic research.
Cancer Epidemiol Biomarkers Prev
2004
;
13
:
898
–905.
8
Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2004.
CA Cancer J Clin
2004
;
54
:
41
–52.
9
Gordon NP, Hiatt RA, Lampert DI. Concordance of self-reported data and medical record audit for six cancer screening procedures.
J Natl Cancer Inst
1993
;
85
:
566
–70.
10
Montano DE, Phillips WR. Cancer screening by primary care physicians: a comparison of rates obtained from physician self-report, patient survey, and chart audit.
Am J Public Health
1995
;
85
:
795
–800.
11
Lipkus IM, Rimer BK, Lyna PR, Pradhan AA, Conaway M, Woods-Powell CT. Colorectal screening patterns and perceptions of risk among African-American users of a community health center.
J Community Health
1996
;
21
:
409
–27.
12
Schoen RE, Weissfeld JL, Trauth JM, Ling BS, Hayran M. A population-based, community estimate of total colon examination: the impact on compliance with screening for colorectal cancer.
Am J Gastroenterol
2002
;
97
:
446
–51.
13
Madlensky L, McLaughlin J, Goel V. A comparison of self-reported colorectal cancer screening with medical records.
Cancer Epidemiol Biomarkers Prev
2003
;
12
:
656
–9.
14
Brown JB, Adams ME. Patients as reliable reporters of medical care process. Recall of ambulatory encounter events.
Med Care
1992
;
30
:
400
–11.
15
Hiatt RA, Perez-Stable EJ, Quesenberry C, Jr., Sabogal F, Otero-Sabogal R, McPhee SJ. Agreement between self-reported early cancer detection practices and medical audits among Hispanic and non-Hispanic White health plan members in northern California.
Prev Med
1995
;
24
:
278
–85.
16
Mandelson MT, LaCroix AZ, Anderson LA, Nadel MR, Lee NC. Comparison of self-reported fecal occult blood testing with automated laboratory records among older women in a health maintenance organization.
Am J Epidemiol
1999
;
150
:
617
–21.
17
Lipkus IM, Samsa GP, Dement J, et al. Accuracy of self-reports of fecal occult blood tests and test results among individuals in the carpentry trade.
Prev Med
2003
;
37
:
513
–9.
18
Hall HI, Van Den Eeden SK, Tolsma DD, et al. Testing for prostate and colorectal cancer: comparison of self-report and medical record audit.
Prev Med
2004
;
39
:
27
–35.
19
Baier M, Calonge N, Cutter G, et al. Validity of self-reported colorectal cancer screening behavior.
Cancer Epidemiol Biomarkers Prev
2000
;
9
:
229
–32.
20
Tisnado DM, Adams JL, Liu H, et al. What is the concordance between the medical record and patient self-report as data sources for ambulatory care?
Med Care
2006
;
44
:
132
–40.
21
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis
1987
;
40
:
373
–83.
22
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
J Clin Epidemiol
1992
;
45
:
613
–9.
23
Partin MR, Casey-Paal AL, Slater JS, Korn JE. Measuring mammography compliance: lessons learned from a survival analysis of screening behavior.
Cancer Epidemiol Biomarkers Prev
1998
;
7
:
681
–7.